|
Session 9-Oral Abstracts
Developments in the Epidemiology of SIV/HIV in AIDS-related Malignancies
Wednesday, 9:30-11:45 am; Room 2004 |
| 9:30 am 24 |
Molecular Epidemiology of SIV Infection in Wild-living Gorillas in Western Equatorial Africa
Lucie Etienne*1, C Neel1,2, Y Li3, J Takehisa3, A Esteban1, R Rudicell3, E Delaporte1, E Mpoudi Ngole2, B Hahn3, and M Peeters1
1UMR145, Inst for Res and Devt and Univ of Montpellier 1, France; 2Projet Prevention du Sida ou Cameroon, Yaoundé; and 3Univ of Alabama at Birmingham, US |
| 9:45 am 25 |
HIV-1 Group P: Confirmation of Group P in Cameroon
A Vallari1, J Yamaguchi1, V Holzmayer1, B Harris1, C Ngansop2, D Mbanya2, N Ndembi3,4, L Kaptue3, S Devare1, and Catherine Brennan*1
1Abbott Diagnostics, Abbott Park, IL, US; 2Univ of Yaounde I, Cameroon; 3Univ des Montagnes, Bangangte, Cameroon; and 4Med Res Council/Uganda Virus Res Inst, Entebbe |
| 10:00 am 26 |
The Role of Recombination in the Emergence of a Complex and Dynamic HIV Epidemic
Ming Zhang*1, B Foley1, A Schultz2, J Macke1, I Bulla2, M Stanke2, B Morgenstern2, B Korber1, and T Leitner1
1Los Alamos Natl Lab, NM, US and 2Univ of Goettingen, Germany |
| 10:15 am 27 |
Cancer Incidence and Cancer-attributable Mortality among Persons with AIDS in the US
Edgar Simard*, R Pfeiffer, and E Engels
NCI, Rockville, MD, US |
| 10:30 am 28 |
Immunodeficiency, HIV RNA Levels, and Risk of Non-AIDS-defining Cancers
Michael Silverberg*1, L Xu2, C Chao2, W Leyden3, M Horberg1, D Klein4, W Towner5, C Quesenberry, Jr3, R Neugebauer3, and D Abrams6
1Kaiser Permanente HIV Initiative, Oakland, CA, US; 2Kaiser Permanente Southern California, Pasadena, US; 3Kaiser Permanente Northern California, Oakland, US; 4Kaiser Permanente Northern California, Hayward, US; 5Kaiser Permanente Southern California, Los Angeles, US; and 6Univ of California, San Francisco and San Francisco Gen Hosp, US |
| 10:45 am 29 |
Effectiveness of a Program to Prevent Cervical Cancer among HIV-infected Women in Zambia
Groesbeck Parham*1,2,3, M Mwanahamuntu2,3, V Sahasrabuddhe4, K King5, K Pfaendler6, V Mudenda2, C Chibwesha1,3, B Chi1,3, S Kapambwe2,3, and J Stringer1,3
1Univ of Alabama at Birmingham Sch of Med, US; 2Univ Teaching Hosp, Lusaka, Zambia; 3Ctr for Infectious Disease Res in Zambia, Lusaka; 4Vanderbilt Univ Sch of Med, Nashville, TN, US; 5Univ of Michigan, Ann Arbor, US; and 6Univ of Cincinnati, OH, US |
| 11:00 am 30 |
HIV Infection Is an Independent Risk Factor for Lung Cancer
Keith Sigel*1, J Wisnivesky1, A Justice2, S Brown3, A Butt4, S Crystal5, D Rimland6, M Rodriguez-Barradas7, and C Gibert8
1Mt Sinai Sch of Med, New York, NY, US; 2Yale Sch of Med, New Haven, CT, US; 3James J Peters VAMC, Bronx, NY, US; 4Univ of Pittsburgh Sch of Med, PA, US; 5Rutgers Univ, Brunswick, NJ, US; 6Emory Univ Sch of Med, Decatur, GA, US; 7Baylor Coll of Med, Houston, TX, US; and 8George Washington Univ Sch of Med, Washingon, DC, US |
| 11:15 am 31 |
A Phase II Study Targeting Vascular Endothelial Growth Factor with the Humanized Monoclonal Antibody Bevacizumab in the Treatment of Patients with HIV-associated Kaposi Sarcoma
Thomas Uldrick*, K Wyvill, P Kumar, W Bernstein, D O’Mahony, M Polizzotto, S Steinberg, S Pittaluga, R Little, and R Yarchoan
NCI, Bethesda, MD, US |
| 11:30 am 32 |
The KAART Trial: A Randomized Controlled Trial of HAART Compared to the Combination of HAART and Chemotherapy in Treatment Naive Patients with HIV-associated Kaposi’s Sarcoma in KwaZulu-Natal, South Africa NCT 00380770
Anisa Mosam*1, F Shaik1,2, T Uldrick2,3, T Esterhuizen1, G Friedland4, D Scadden5, J Aboobaker1, and H Coovadia1,6
1Univ of KwaZulu-Natal, Durban, South Africa; 2CAPRISA and Columbia Univ-South Africa Fogarty AIDS Intl Training and Res Prgrm; 3Columbia Univ, Mailman Sch of Publ Hlth, New York, NY, US; 4Yale Sch of Med, New Haven, CT, US; 5Harvard Med Sch, Boston, MA, US; and 6Univ of the Witwatersrand, Johannesburg, South Africa |
|
